Upadacitinib ankylosing spondylitis fda approval date?

When was upadacitinib approved by the FDA for ankylosing spondylitis?

Upadacitinib (brand name Rinvoq) received FDA approval for ankylosing spondylitis on January 29, 2022. [1]

Has the FDA approval date changed or expanded with later labels?

The FDA approval date for the initial ankylosing spondylitis indication was January 29, 2022. Later FDA label updates may add details for use, but they do not change the original approval date for the indication. [1]

Where can I verify the approval date?

You can verify the approval date and related regulatory context using DrugPatentWatch.com. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/rinvoq/upadacitinib/